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ABSTRACT
Chronic administration of diisopropyl fluorophosphate (DFP) at
72 hour intervals for a total of 14 doses resulted in a reduction in
the number of central muscarinic receptors in mice as measured by the
specific binding of [3H]Quinuclidinyl benzilate (QNB) to cortical tis
sue homogenates (pmole/mg protein). The number of cholinergic receptors
were reduced significantly by 12% in DFP treated animals (0.687 + 0.018
pmoles/mg) as compared to vehicle treated controls (0.781 +0.016 pmoles/
mg) after the sixth dose of DFP (Day 17). The decrease in the number of
central cholinergic receptors was maximal after the 8th dose of DFP
(Day 23), and central cholinergic receptor number remained significantly
depressed through the 14th dose of DFP. DFP administration was termina
ted after the 14th dose (Day 40), and the number of central cholinergic
receptors increased to 0.853 + 0.013 pmole/mg after 6 days and returned
to pretreatment levels (0.934 + 0.019 pmoles/mg) 13 days after the last
dose of DFP. This study demonstrated that the number of central musca
rinic receptors could be reduced by chronic DFP treatment, and binding
could return to control levels after drug treatment was terminated.
Hypoxia survival times were used to assess central cholinergic ac
tivity. Therefore the next study was designed to examine the relation
ship between DFP-induced alterations in central muscarinic receptor
number and hypoxia survival times in mice during and following chronic
administration with DFP at 72 hour intervals.
At the first time point examined (Day 5, after the second dose of
DFP) hypoxia survival times were significantly increased in DFP treated
mice while receptor numbers were not significantly altered. Survival
times of mice in hypoxic conditions were significantly increased after
the 6th (Day 17), 12th (Day 35) and 14th doses (Day 41) of DFP, whereas
the number of central cholinergic receptors was significantly reduced.
The data from these three time points demonstrated that there is an
inverse relationship between hypoxia survival times and the number of
central muscarinic cholinergic receptors. Hypoxia survival times were
not significantly altered 20 days (Day 60) after the last dose of DFP
was administered, but the number of muscarinic receptors remained
significantly depressed. On Days 5 and 60 the inverse relationship
between hypoxia survival times and the number of central muscarinic
receptors was not apparent.
These studies demonstrate that the number of central cholinergic
receptors can be altered during and following chronic DFP administra
tion, but that hypoxia survival times were not a clear indicator of
the number of central muscarinic receptors.
INTRODUCTION
There are few experimental animal models which reflect the phy
siological deficits characteristic of senile dementia. Development
of an animal model is necessary if new drugs to treat senile dementia
are to be developed. A strong link between senile dementia of the
Alzheimer type in humans and the presence of cholinergic hypoactivity
has been established (1). The objectives of this study are to develop
an animal model with a chemically induced cholinergic subsensitivity
(reduction in the number of central muscarinic receptors) similar to
that observed in senile dementia patients and to evaluate the hypoxia
screen as an indicator of these chemically induced changes in receptor
numbers.
Cholinergic Pharmacology
Acetylcholine is a neurotransmitter in the brain. The synthesis
of acetylcholine (2) requires the activation of acetate to form acetyl
CoA, which then combines with choline in the presence of the enzyme,
choline acetyl transferase to form acetylcholine and CoA. Acetylcholine
is stored in membrane limited synaptic vesicles. A nerve impluse upon
reaching a nerve ending causes these vesicles to fuse with the synaptic
membrane and empty their contents into the synaptic cleft. Acetylcho
line then diffuses across the synaptic cleft and binds to specific ace
tylcholine receptors on the postsynaptic neuron to produce membrane de
polarization. Postsynaptic acetylcholine receptors in the brain are
classified as muscarinic receptors (Figure 1). Soon after this neuro
transmitter receptor interaction, acetylcholine is hydrolyzed to acetic
FIGURE 1
Schematic representation of a cholinergic neuron.
10
11
12
&
13
Activation of acetate to form acetyl CoA.
The enzyme choline acetyl transferase catalyzes the conversion of
Acetyl CoA and choline to form acetylcholine.
A nerve impulse reaches the nerve ending causes the synaptic
vesicle to fuse with the synaptic membrane.
Synaptic vesicle releases acetylcholine into the synaptic cleft.
In the synaptic cleft, acetylcholine is hydrolyzed to acetic
acid and choline by acetylcholinesterase.
Acetylcholine that successfully crosses the synaptic cleft binds
to the postsynaptic muscarinic receptor.
Postsynaptic muscarinic receptor.
Drugs such as DFP, neostigmine and physostigmine inhibit
acetylcholinesterase.
Drugs such as atropine, glycopyrrol ate, and QNB are cholinergic
antagonists and bind at the postsynaptic muscarinic receptor,
but have no intrinsic activity.
Drugs such as oxotremorine, pilocarpine and carbachol are
cholinergic agonists which mimic the action of acetylcholine.
Receptor bound to a cholinergic antagonist which results in no
biological response.
Acetylcholine or cholinergic agonist bound to a muscarinic
receptor which initiates a biological response.
DFP
Physostigmine
Neostigmine
Acetylcholinesterase
Inhibition (8)
Synaptic
Cleft
Cholinergic
Antagonist (9)
Atropine
QNB
Glycopyrrolate
Acetyl CoA + Choline
(1) iw (2)
CHOLIUE ACETYLTRANSFERASE
Free Acetylcholine
Acetylcholine
Choline
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nergic,
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acid and choline by acetylcholinesterase located on the postsynaptic
membrane.
Drugs can impair, mimic, or enhance the cholinergic neurotransmis
sion process. The synthesis of acetylcholine can be enhanced by a cho
line supplement to the diet while the hemacolinium compound, HC-3,
interferes with acetylcholine synthesis by blocking the uptake of cho
line by the presynaptic neuron (2). The release of acetylcholine is
altered by Ca+2 and Mg+2 ions and by the botulinus toxin (2). Drugs
which have the ability to inhibit acetylcholinesterase reversibly and
irreversibly are called anticholinesterase agents (Figure 2). Physo
stigmine and neostigmine are reversible acetylcholinesterase inhibitors,
while diisopropyl fluorophosphate (DFP), an organophosphate (Figure 3),
is an irreversible inhibitor (2,3). Reversible acetylcholinesterase
inhibitors acetylate the enzyme and form a transient complex with the
surface of the enzyme. The drug then competes with acetylcholine for
the enzyme's active site. The acetyl ated enzyme can react with water
to reactivate the enzyme. The irreversible acetylcholinesterase in
hibitor phosphorylates the enzyme making the enzyme-inhibitor complex
irreversible. In either mechanism of action, acetylcholinesterase in
hibitors slow down or prevent destruction of acetylcholine, thus re
sulting in increased levels of neurotransmitter in the synaptic cleft.
A number of drug interactions can take place at the muscarinic re
ceptor on the postsynaptic membrane (Figure 1). Drugs which bind to
this receptor and mimic the action of acetylcholine are called cholin
ergic agonists or cholinomimetics. Examples of cholinergic agonists
are pilocarpine, oxotremorine and muscarine (2). Drugs which block
11
FIGURE 2
Effect of acetylcholinesterase inhibition on acetylcholine hydrolysis.
Steps invovled in the hydrolysis of acetylcholine (ACh) by acetylcho
linesterase (AChE) (I), and in the inhibition of AChE by carbamyl
ester (II), and organophosphorus (III) agents.*
I. The substrate, ACh, combines with an active unit of the enzyme to
form a complex (A) by electrostatic attraction between the N+ atom
of the choline moiety and the anionic site of the enzyme, and the
electrophilic C atom of the carboxyl group and a protonated acidic
group (-G-H) of the esteratic site; choline is then split off
(step 2), leaving the acetylated enzyme (B), which reacts rapidly
with water (step 3) to produce acetic acid and the regenerated
enzyme.
II. Neostigmine and related ammonium- or amino-carbamyl esters react
with the enzyme in the same manner as does the substrate (step 1
and 2); however, the dimethyl carbamoyl enzyme (II-B) reacts with
water (step 3) at less than a millionth the rate of the corre
sponding acetylated form (I-B).
III. DFP and similar organophosphorus inhibitors react only at the
esteratic site to form a phosphorylated enzyme; in the case
of diisopropylphosphoryl-AChE (I II-B), essentially no sponta
neous hydrolytic reactivation occurs.
Heavy, light and dash arrows represent extremely rapid, intermediate,
and extremely slow or insignificant reaction velocities, respectively.
*See Reference 3.
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FIGURE 3
Chemical structures of organophosphates and DFP.
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the receptor by binding at the site but have no intrinsic or biological
activity are muscarinic antagonists or cholinolytics. Compounds includ
ed in this class of inhibitors are quinuclidinyl benzilate, atropine,
glycopyrrolate, and scopolamine (2).
Relationship Between Disease States and Central Cholinergic Activity
The dementias constitute one of the most prevalent groups of dis
eases today. The clinical state of dementia is characterized by the
gradual impairment of memory and learning, loss of intellectual and
cognitive functions and disorientation (1). There are approximately
one million persons in the United States with dementia. Dementia is
one of the most common syndromes in the elderly, afflicting 5% of the
over 65 year old population in the United States and Northern Europe (4).
As the average age of individuals in the population increases, this
phenomenon of dementia could be extrapolated to show a tripling of the
incidence of this syndrome by the year 2050.
Historically, the term Alzheimer's disease referred exclusively to
presenile dementia (progressive dementia in patients under 65 years of
age), whereas the term senile dementia was applied to those 65 and over.
Because the two conditions are clinically, neurologically, pathologi
cally, and biochemically alike they are now believed to be the same
disease (5). Alzheimer's disease is named for Alois Alzheimer, who
in 1906 first described this condition and recognized it as a disease
(1). This disease is characterized by neuropathological and neurochem
ical alterations in areas of the brain associated with memory (6).
Neuropathological effects include gross atrophy of the cerebral cortex
and degeneration of the neurons in the hippocampus which play an impor
tant role in memory function (6).
16
Recently, the roles of acetylcholine and cholinergic function has
been linked to memory and learning tasks (7). Impaired cholinergic
function may be an important contributor to geriatric memory deficits.
Neurochemical alterations associated with Alzheimer's disease involve
a general cholinergic hypoactivity characterized by decreased activity
of cholineacetyl transferase, acetylcholinesterase, and decreased musca
rinic receptor binding (7-9). This age related decrease in central cho
linergic activity is particularly severe in patients with senile demen
tia, but may be an underlying cause of other memory disorders in the
aged.
Further evidence for the relationship between memory and central
cholinergic activity is supported by numerous pharmacological studies
in man showing a decrement in memory processes following administration
of cholinergic antagonists and improvements in some memory functions
following administration of cholinergic agonists (10-12).
Animal Models For Senility
No known animal model mimics all or even most of the behavioral,
neurochemical and neuropathological defects of senile dementia (13).
Investigators have studied certain of these defects in old animals of
a variety of species in an attempt to identify characteristics that
are in one way or another similar to the changes characteristically
seen in the senile human. For example, depressed acetylcholine syn
thesis has been detected in senescent C57BL/6J and BALB/c mice (14).
This decrease has been correlated with behavioral deficits and may
contribute to brain dysfunction accompanying senescence (14). However,
even this approach has been hampered by the limited supply of naturally
17
aged animals and the expense of maintaining such colonies for the ex
tended periods of time required for study.
Cholinergic subsensitivity is one characteristic of senile demen
tia in humans that is also in evidence in some species of naturally
aged animals (13). Cholinergic subsensitivity can be defined as a con
dition in which there is a reduction in the number of central muscarin
ic cholinergic receptors (Figure 4). Patton and Rang (15) were the
first to identify the central muscarinic acetylcholine receptor by
demonstrating the presence of a high affinity binding sites for re
versible tritiated muscarinic antagonists. [3H]Quinuclidinyl benzilate:
(QNB), a muscarinic antagonist, was described by Yamamura and Snyder to
have high affinity and specificity for muscarinic binding sites in rat
brain homogenate (16). [3H]QNB binding has been utilized in a number
of studies to assess central cholinergic activity in experimental
animals (17-20).
A drastic reduction in the time required to develop cholinergic
subsensitivity is observed when experimental animals are chronically
treated with DFP (17-18) compared to waiting for development of cho
linergic subsensitivity in naturally aged animals. Numerous studies
(17-19) have confirmed that chronic treatment of experimental animals
with DFP inhibits cholinesterase activity, increases acetylcholine
levels, and decreases the number of central muscarinic receptors.
Ehlert et al . , (20) suggested that DFP-induced alterations in musca
rinic binding in the brain are caused by acetylcholinesterase inhib
ition and the resulting accumulation of acetylcholine at the choliner
gic synapse. Those animals receiving chronic DFP treatment showed a
18
FIGURE 4
Schematic representation of DFP-induced cholinergic subsensitivity.
1. Cholinergic transmission-normal cholinergic transmission with
acetylcholine (ACh) inactivated by acetylcholinesterase (AchE).
2. DFP Subsensitivity-DFP inactivated acetylcholinesterase (AchE),
acetylcholine (Ach) accumulated in synapse, resulting in a
reduction in the number of muscarinic postsynaptic receptors.
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25-30% reduction in the number of central muscarinic acetylcholine re
ceptors. Thus, it appears that chronic treatment with DFP creates a
cholinergic hypoactivity similar to the cholinergic subsensitivity in
humans. These animals with artificially induced cholinergic subsensi
tivity may provide a suitable drug induced "senility" model to screen
drugs for potential pharmacological activity in the treatment of cer
tain aspects of senile dementia.
Screens Used to Assess Central Cholinergic Activity: Hypoxia Test
1. Relationship Between Survival Time and Central Cholinergic
Activity
Centrally acting cholinergic agents have been demonstrated to pro
foundly alter survival times of animals exposed to hypoxia (atmosphere
96% nitrogen, 4% oxygen). Under this condition death is due apparently
to impairment of cerebral function ultimately resulting in respiratory
arrest (22).
Several lines of evidence suggest that survival times under hypox
ia are mediated by a central cholinergic mechanism. Physostigmine, a
reversible acetylcholinesterase inhibitor, causes a dose related in
crease in survival time of experimental animals during hypoxia (21-23).
This effect appears to be due to the accumulation of acetylcholine at
central cholinergic synapses (21). The effect of physostigmine on sur
vival time is not related to the drug's action on peripheral cholinergic
synapses, since the effect is not mimicked by neostigmine, a reversible
acetylcholinesterase antagonist that does not penetrate the blood brain
barrier (21). Further studies demonstrate that the peripheral cholin
ergic antagonist, glycopyrrolate, does not prevent the protective ef
fect of physostigmine in the hypoxia test (21). In contrast to
21
glycopyrrolate, atropine a cholinergic antagonist which can pass the
blood brain barrier, did reduce physostigmine enhanced survival times
(21). These studies provide evidence that enhanced survival is a cen
tral cholinergic phenomenon since manipulation of the peripheral cho
linergic nervous system has no effect on hypoxia survival times (Ta
ble 1).
2.- Mechanism By Which Central Cholinergic Activity Alters Sur
vival Times In The Hypoxia Test
Scremin et^ aj_. (24) have shown that cholinergic drugs can signif
icantly alter cerebral blood flow and thus may alter survival times by
increasing oxygen transport to the central nervous system. By measur
ing local blood flow in the cerebral cortex of rats they demonstrated
increases in cerebral blood flow upon administration of cholinomimetic
drugs (24). Atropine was shown to block cerebral vasodilation stimu
lated by cholinomimetics.
Gibson and Blass (25) hypothesized that a reduction in oxygen sup
ply to the brain during hypoxia reduces the synthesis of acetylcholine
in vivo. This reduction in acetylcholine synthesis is related to an
impairment of carbohydrate oxidation. Pretreating animals with phy
sostigmine delays death from hypoxia (25), which suggests that hypoxia
interferes with the synthesis of acetylcholine in the brain. Thus,
although several mechanisms may contribute to alterations in hypoxia
survival times, it appears that these mechanisms are linked to the
central cholinergic system.
22
TABLE 1: EFFECT OF CHOLINERGIC DRUGS ON CHOLINERGIC NEUROTRANSMITTER LEVELS AND
HYPOXIA SURVIVAL TIMES*
DRUG SITE OF ACTION
HYPOXIA SURVIVAL
NEUROTRANSMITTER TIMES
PHYSOSTIGMINE CENTRAL ACETYLCHOLINESTERASE
INHIBITOR
t ACH I
NEOSTIGMINE PERIPHERAL
\CETYLCHOL INESTERASE INHIBITOF
Iach
GLYCOPYRROLATE
+
PHYSOSTIGMINE
PERIPHERAL
CHOLINERGIC ANTAGONIST
CENTRAL ACETYLCHOLINESTERASE
INHIBITOR
JACH 1
ATROPINE SULFATE
+
PHYSOSTIGMINE
CENTRAL CHOLINERGIC AMTAGONIS1
CENTRAL ACETYLCHOLINESTERASE
INHIBITOR
|ach
SEE REFERENCE 21
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MATERIAL AND METHODS
Experimental Animals
Male C57BL/6J mice (Jackson Laboratory) 10 weeks old and weighing
25-30 grams were utilized in these experiments. The animals were
housed (5 per cage) in stainless steel cages under a 12 hour light/
dark (6 a.m. -6 p.m.) schedule at a temperature of 21 + 2C and rel
ative humidity 30-60%. Standard (Purina Rodent Chow) food and water
were available ad libidum.
Animals used in chronic studies received 1 mg/kg diisiopropyl flu-
orophosphate-DFP (Aldrich Chemical Co.) or 10% propylene glycol dis
solved in 0.9% saline (vehicle control animals). Injections were ad
ministered intraperitoneal ly in a volume of 0.01 ml/gram body weight
between 7-9 a.m. Animals used in acute studies were injected intra
peritoneal! y with a volume of 0.01 ml /gram body weight. In these acute
studies mice dosed with 1 mg/kg DFP were compared to vehicle (10% pro
pylene glycol dissolved in 0.9% saline) treated animals. In a second
acute study, mice received 10 mg/kg atropine sulfate (Sigma Chemical
Co.) or 0.9% saline which served as control.
Animal Sacrifice and Tissue Removal
The number of muscarinic receptors was assayed in brain homogenates
taken from mice that were sacrificed by decapitation 24 hours after dos
ing except where otherwise indicated. Following decapitation, the brain
tissue from each mouse was removed and the cerebellum was dissected away
and discarded. The cerebrum was divided in half longitudionally and
each cerebral hemisphere was placed in minivials and rapidly frozen in
24
a dry ice methanol bath (-72C). The minivials were stored at -20C
for no more than one week.
Brains were assayed for specific [3H]QNB (3-Quinuclidinyl benz
ilate) binding according to the method of Yamamura and Snyder (18)
with minor modifications. [3H]QNB (New England Nuclear, Specific ac
tivity 29.4-40.2 Ci/mmole), a specific muscarinic antagonist, was
utilized to assess the affinity and number of muscarinic binding sites
in cortical homogenates. One cerebral hemisphere from each mouse was
placed in a 5 ml Potter Elvehjem glass homogenizer fitted with a Teflon
pestle and were homogenized in 3 ml ice cold (4C) 0.32 M sucrose for
one minute at high speed (T-Line Laboratory stirrer motor). Tissue ho
mogenates were then placed in a 10 ml borosilicate glass test tube and
centrifuged for 10 minutes at 1,000 x g in an International PR-6000
centrifuge at 5C. The pellet (crude nuclear fraction) was discarded
and the supernatant (SI) containing crude synaptosomes was homogenized
with the Brinkman Polytron (PCU-2-110, setting 5, for 30 seconds).
To assay for the total number of muscarinic receptors, a homoge-
nate was incubated in 50 mM Na-K phosphate buffer pH 7.4 containing a
concentration of 0.7 nM [3H]QNB. The final incubation volume was 2 ml.
Nonspecific binding of QNB to brain homogenate was determined in the
presence of 1 x 10-6 M atropine sulfate. Atropine binds to all avail
able specific muscarinic receptor sites in the tissue homogenate and
therefore any [3H]QNB bound to the tissue sample in the presence of
atropine was defined as nonspecific binding.
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Following an hour incubation at 25C, the binding reaction was
terminated by pouring the contents of each assay tube on a GF/B filter
(Whatman). The [3H]QNB bound to membrane protein remains on the fil
ter, while free [3H]QNB is washed away. Each filter was positioned
over a manifold (Millipore Model 3205) filtering device under vacuum.
The assay tube was washed four times with 4 ml ice cold 50 mM Na-K
phosphate buffer pH 7.4 and each wash was applied to the filter. The
filters were transferred to 20 ml polypropylene scintillation vials
(Fisher Scientific) containing 9 ml J. T. Baker Uni/Verse scintillation
cocktail. The vials were maintained at room temperature for 1-3 hours
to allow counts to dissolve from the filters, vortexed and counted in
a Beckman LS-9000 liquid scintillation spectrometer using a modified
tritium program to determine disintegrations per minute.
A Scatchard analysis was utilized to determine the affinity and
number of specific [3H]QNB receptors in cortical homogenates (26).
Specific [3H]QNB binding to tissue homogenates from different
experimental groups was expressed as the mean of the group + the stan
dard error of the group. A Student-t analysis was utilized to deter
mine the statistical significance between experimental groups. A p
value < .05 between experimental groups was considered to be a signif
icant difference.
Protein levels were determined by the method of Lowry ejt al_. (27)
using bovine serum albumin (Sigma Chemical Co.) as the standard.
Hypoxia Studies
A test chamber consisting of a clear plastic 22 x 21.5 x 20 cm.
box with a cover was utilized for the hypoxia screen. Two minutes
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prior to the test period a gas mixture containing 96% nitrogen and 4%
oxygen (Union Carbide Corporation, Linde Division) was introduced into
the test chamber through a valve near the bottom of the chamber and a
valve at the top of the chamber was left open to allow the gases to
escape. Gas pressure was maintained at 10 pounds per square inch with
a Matheson model 8-590 regulator and flow was controlled with a Linde
Model L32 flowmeter at 0.01 m3 /minute. Room temperature was maintained
at 24 + 2C. The testing period began as five mice were placed into
the screening chamber and the top valve was closed, while the gas mix
ture continued to flow into the screening chamber. Survival times of
the mice to hypoxic conditions were assessed to the nearest one tenth
of a minute. Survival time was recorded to a maximum of fifteen min
utes. Student t was the statistical test (p<.05) was used to analyze
acute and chronic alterations in hypoxia survival times. A two way
analysis of variance (ANOVA) was the statistical test (p<.05) utilized
for the analysis of survival times collected in the study of effect of
time of day on hypoxia lethality. In that study survival times of mice
were collected at 15 minute intervals during a two hour period on con
secutive days.
Dosing and Tissue Sampling: Protocol for DFP Induced Subsensitivity
One hundred and fifty mice were dosed on Day 1. Mice were divided
into two groups: seventy-five mice received DFP treatment, the remain
der received drug vehicle injection every 72 hours following the first
injection which was designated as Day 1. At various time intervals af
ter the first injection of drug-vehicle or DFP, five mice from each
treatment group were sacrificed and the number of central cholinergic
27
receptors was assayed utilizing a [3H]QNB binding procedure. Figure 5
illustrates the dosing and sacrifice regimen. Following the first dose
the number of central cholinergic receptors was assayed one and twenty
four hours after the injection. Subsequent assays for the number of
central cholinergic receptors were obtained at six day intervals fol
lowing the first injection until the study was terminated on Day 65.
DFP and vehicle control injections of mice were discontinued on Day 40.
Dosing and Tissue Sampling: Protocol for the Correlation of DFP
Induced Subsensitivity and Hypoxia Survival Times
Two hundred mice were dosed according to the schedule that was
used to induce cholineric subsensitivity. One hundred mice received
drug treatment, the remainder received drug vehicle and served as con
trols. Twenty four hours after an injection on Days 5, 17, 35, 41 and
60, fifteen mice from each vehicle control and DFP-treated groups were
tested utilizing the hypoxia test, and an additional five mice were
sacrificed from each experimental group in order to determine central
cholinergic receptor number (Figure 6). DFP and vehicle control in
jections were discontinued on Day 40.
28
FIGURE 5
Dosing and tissue sampling: protocol for DFP-induced cholinergic
subsensitivity. C57BL/6J mice were dosed every 72 hours following
the initial dose on Day 1 (j). Mice were sacrificed and [3H]QNB
binding was assayed at various time points ( +)
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FIGURE 6
Dosing and tissue sampling: Protocol for the correlation of DFP-
induced cholinergic subsensitivity and hypoxia survival times.
C57BL/6J mice were dosed every 72 hours following the initial
dose on Day 1 ($) Mice were sacrificed and [3H]QNB binding
was assayed at various time points (A)-
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RESULTS
Preliminary Hypoxia Screen Studies
Exposure of mice to hypoxic conditions generally produced the fol
lowing series of changes that ultimately led to respiratory failure.
Mice placed in the hypoxia chamber remained relatively stationary
until several minutes into the testing period, then they began to
explore the chamber until they lost their righting reflex. At this
point obvious signs of cyanosis, writhing and gasping were evident.
The final moments before respiratory failure were characterized by
spontaneous muscular contraction and intermittent gasping. Survival
times under hypoxic conditions were recorded at the last respiratory
movement.
These experiments were designed to examine the effect of acute
administration of cholinergic drugs on hypoxia survival times in mice.
Figure 7 shows the survival time of mice injected with atropine
(10 mg/kg) or saline intraperitoneal ly (i.p.) 30 minutes prior to
exposure to hypoxic conditions. The mean survival time of control
mice was 5.4 + 0.4 minutes while the mean survival time for atropine
treated mice was 3.6 +0.2 minutes. Intraperitoneal injections of
10 mg/kg atropine sulfate in mice caused a significant decrease in
survival time of mice exposed to hypoxic conditions compared to
saline-injected control animals (Student t p<.05). This dose of
atropine did not produce any overt behavioral changes.
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FIGURE 7
Hypoxia survival time of C57BL/6J mice (n=10) injected with 0.9%
saline or 10 mg/kg atropine sulfate injected intraperitoneal^
in mice 30 minutes prior to exposure to hypoxic conditions.
* Significant p<.05, Student t test.
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The effect of 1 mg/kg DFP i.p. administration in mice on hypoxia
survival times was examined in the next experiment. Injections of
DFP into mice 30 minutes prior to exposure to hypoxia significantly
increased survival time compared to vehicle-control mice (Student t
p<.05). Figure 8 shows the survival times of vehicle-control mice
was 6.9 + 0.4 minutes while DFP treated mice survived an average of
9.8 +_ 0.8 minutes. No cholinergic symptomology was evident at this
dose of DFP.
The data summarized in the acute atropine and DFP studies were
collected over a two day period. On each day, five control mice were
tested in the hypoxia chamber and five drug treated mice were tested
immediately thereafter. Data were pooled to obtain n=10 for each ex
perimental group.
Studies have shown that survival times vary with time of day,
therefore the next experiments were designed to study the variations
of survival times during the time intervals of the day that would be
used in future studies. A group of 100 nontreated mice were divided
into two experimental groups and studied on successive days. Testing
began at 7:45 a.m. and survival times were assessed at fifteen minute
intervals until 10 a.m. Results are summarized in Table 2. There
were no significant variations in hypoxia survival times (ANOVA,
p < .05) during the time intervals studied. Hypoxia survival times
followed a normal distribution (Figure 9). Hypoxia survival times
recorded during the two hour period on Day 1 yielded a mean survival
time of 5.4 + 0.1 minutes with a range of 3.4-7.4 minutes, on Day 2
the mean survival time was 5.5 +0.1, range 4.0-7.4 minutes. All sub
sequent hypoxia testing was scheduled during this time interval.
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FIGURE 8
Survival time of C57BL/6J mice (n=10) with 10% propylene-glycol
dissolved in 0.9% saline or 1 mg/kg DFP injected intraperitoneally
in mice 30 minutes prior to exposure to hypoxic conditions.
* Significant p<.05, Student t test.
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TABLE 2: HYPOXIA LETHALITY IN C57BL/6J MICE AND TIME OF DAY
TIME DAY N SURVIVAL TIMES (MINUTES)
A.M.
7:45 1 5
RANGE MEAN S.E.
4.1-6.5 5.6 0.5
2 5 4.7-6.5 5.6 0.3
8:00 1 5 4.6-5.7 5.1 0.2
2 5 4.5-6.8 5.5 0.4
8:15 1 5 4.2-5.6 5.0 0.3
2 5 4.0-6.1 5.2 0.3
8:30 1 5 3.4-7.3 5.3 0.7
2 5 4.3-6.0 5.3 0.3
8:45 1 5 4.8-6.6 5.5 0.3
2 5 4.7-6.0 5.1 0.2
9:00 1
2
5
5
4.7-7.4
5.8-6.5
5.9 0.5
6.1 0.4
9:15 1
2
5
5
5.3-6.2
5.0-7.4
5.7 0.2
6.0 0.4
9:30 1
2
5
5
4.4-5.5
5.1-5.4
5.1 0.4
5.2 0.1
9:45 1
2
5
5
4.7-6.7
5.1-6.4
5.7 0.3
5.8 0.2
10:00 1
2
5
5
4.0-6.1
5.0-6.9
5.2 0.3
5.5 0.4
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FIGURE 9
Histogram of hypoxia survival times of 100 nontreated C57BL/6J mice
observed on two consecutive days from 7:45 to 10:00 a.m. showing an
approximate normal distribution. The number of observations (y-axis)
are presented for survival times with the midpoint of each range of
survival time (x-axis).
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Preliminary [3H1QNB Binding Studies
A Scatchard analysis of [3H]QNB binding to cortical homogenates
was used to determine the number and affinity of central muscarinic
receptors. [3H]QNB binding to cortical muscarinic receptors was
measured at seven concentrations of radioligand. The Scatchard plot
of [3H]QNB binding to the muscarinic receptor in cortical homogenates
of C57BL/6J mice resulted in a straight line which suggested a single
species of independent receptors. The number of binding sites is 1.26
pmoles/mg protein with affinity of 0.27 nM (Table 3, Figure 10).
In order to assess the number of cholinergic receptors in mouse
cortical homogenates, varying amounts of [3H]QNB ligand were added to
the incubation mixture to determine ligand concentration to be used in
further binding studies (Table 4, Figure 11). Specific [3H]QNB bind
ing in mouse cortical homogenates was saturable with increasing con
centrations of QNB, while nonspecific binding, in the presence of
1 x 10-6 M atropine sulfate, was not saturable and increased linearly
with increasing concentration of [3H]QNB. To measure the total number
of muscarinic receptors in cortical homogenates a final concentration
of 0.7 nM was selected. At this concentration less that 2% of [3H]QNB
was bound nonspecifically and less than 30% of the total concentration
of [3H]QNB was bound to muscarinic receptors in mouse cortical homoge
nates.
Linearity of [3H]QNB binding to cortical homogenates was checked
using a range of protein concentrations varying from 0.1 to 1.0 mg
protein/assay. Total and nonspecific binding were measured at various
42
TABLE 3: SCATCHARD PLOT-^H JQNB BINDING TO MUSCARINIC RECEPTORS IN C57BL/6J MOUSE
CORTICAL HOMOGENATES
f3H JQNB INPUT f3HJQNB FREE f3HJQNB BOUND
(FMOLE) (FMOLE/nM) (PMOLE/MG)
68
957
1287
2675
6759
9969
14050
0.02 0.07
0.32 0.70
0.46 0.81
1.10 1.03
3.12
4.72
6.76
1.12
1.16
1.23
f3HJQNB BOUND/FREE
(PMOLE/MG)
nM
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FIGURE 10
Scatchard plot of [3H]QNB binding to muscarinic receptors in
C57BL/6J mouse cortical homogenates. [3H]QNB bound in pmole/mg
protein (x-axis) vs. [3H]QNB Bound/Free (y-axis) in (pmole/mg
protein)/nM. The number of binding sites Bmax is 1.26 pmole/mg
protein with affinity Kj of 0.27 nM. The slope of the line
obtained from linear regression analysis is -3.70.
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TABLE 4: SPECIFIC BINDING OF f3HJQNB TO C57BL/6J MOUSE CORTICAL HOMOGENATES
AS A FUNCTION OF f3H J QNB CONCENTRATION
3HJQNB
(nM)
0.08
0.18
0.37
0.56
0.72
1.58
3.73
5.44
7.57
f3HJQNB BOUND
(PMOLE/MG PROTEIN)
SPECIFIC
0.12
0.28
0.55
0.75
0.83
1.15
1.17
1.12
1.13
NONSPECIFIC
0.01
0.01
0.01
0.01
0.01
0.03
0.05
0.08
0.13
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FIGURE 11
Specific -^ and nonspecific+ [3H]QNB binding in C57BL/6J
mouse cortical homogenates as a function of increasing [3H]QNB
concentration. Specific [3H]QNB binding is saturable with in
creasing [3H]QNB concentration and nonspecific binding increases
linearly with [3H]QNB concentration and is not saturable.
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concentrations of protein. Specific [3H]QNB binding was linear be
tween 0.1 and 0.5 mg of tissue protein (Table 5, Figure 12). The
protein concentration used in subsequent assays varied between
0.4-0.45 mg protein/assay tube.
I3H]QNB Binding Studies: DFP-Induced Central Cholinergic Subsensitivity
This study was designed to examine the time course of development
and recovery of DFP-induced central cholinergic subsensitivity in
C57BL/6J mice. Table 6 and Figure 13 summarize the results of this
study. The 17th day of treatment (6th dose of DFP) was the first
time point at which there was a significant difference in the number
of central cholinergic receptors in vehicle-treated animals compared
to DFP-treated animals. Maximal DFP-induced cholinergic subsensitivity
was detected by the 23rd day of drug treatment and remained constant
until after the 41st day of the experiment. At these time points QNB
binding to cortical muscarinic receptors of DFP-treated mice was de
creased by 20-25% compared to vehicle control animals. The levels of
[3H]QNB binding to central muscarinic receptors in cortical homogenates
of DFP-treated animals continued to be significantly reduced when com
pared to vehicle control animals 7 days (Day 47) after the last in
jection. The number of central cholinergic receptors was 15% less in
DFP-treated animals compared to vehicle control mice at this time.
The number of cholinergic receptors at this time point was signifi
cantly greater than QNB binding values on Days 23 through 41. Thir
teen days (Day 53) after the final injection of DFP the level of [3H]
QNB binding in cortical homogenates obtained from DFP-treated mice
was not significantly different than the binding levels in vehicle
control mice.
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TABLE 5: SPECIFIC BINDING OF f3HJQNB AS A FUNCTION OF TISSUE PROTEIN CONCENTRATION
MG PROTEIN
0.196
0.245
0.492
0.738
0.984
MEAN DPM S.E. PMOLE0HJQNB
TOTAL NONSPECIFIC SPECIFIC DPM BOUND
10556 213
14330 332
27270 117
31649 950
34598 171
548 45
555 48
618 78
617 14
718 31
10008
13775
26652
31032
33880
0.155
0.213
0.412
0.480
0.524
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FIGURE 12
Results of specific [3H]QNB binding to muscarinic receptors
in C57BL/6J mouse cortical homogenate as a function of protein
concentration. Specific [3H]QNB binding was linear between
0.1 and 0.5 mg of tissue protein.
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TABLE 6: TIME COURSE OF DEVELOPMENT AND RECOVERY OF DFP-INDUCED CENTRAL CHOLINERGIC
SUBSENSITIVITY OF C57BL/6J MICE
SPECIFIC BINDING 0Ff3HJQNB
DAY BOSE # OF DFP CONTROL (PMOLE/MG) DFP (PMOLE/MG) X CONTROL
1 1 1.132 0.038 1.125 0.027 99.4 2.4 Sacrificed one
hour post dose
2 1 1.143 0.041 1.152 0.050 100.8 4.4 SACRIFICED 24
HOURS POST DOSE
5 2 0.986 0.012 0.971 0.008 97.9 0.6 it
11 4 0.805 0.036 0.725 0.023 90.1 2.8 ii
17 6 0.781 0.016 0.687 0.018 88.4 2.4* n
23 S 0.892 0.028 0.708 0.016 79.4
1.8*
a
29 10 0.886 0.040 0.676 0.016 76.3 +
1.8*
35 12 0.909 0.020 0.686 0.032 75.4
3.5*
n
41
47
14
6 DAYS POST
FINAL DOSE
OF DFP
0.911 0.010
0.980 0.023
0.725 0.010
0.835 + 0.013
79.6
1.1*
*
85.2 1.3
SACRIFICED 24
40URS AFTER THE
.AST DOSE OF DFP
53 13 DAYS POST
FINAL DOSE
OF DFP
0.942 0.007 0.934 0.019 99.1 2.0
60 20 DAYS POST
FINAL DOSE
OF DFP
1.043 0.019 1.045 + 0.032 100.6 3.1
65 25 DAYS POST
FINAL DOSE
OF DFP
1.080 0.062 1.112 0.041 103.4 4.1
* SIGNIFICANT STUDENT T TEST P<05
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FIGURE 13
Results of time course of development and recovery of DFP-induced
central cholinergic subsensitivity in C57BL/6J mice (n=5).
* Significant p<.05 Student t test.
54
10 15 20 25 30 35 40 45
Time (days)
50 55 60 65
55
Table 6 also illustrates [3H]QNB binding to cortical muscarinic
receptors in vehicle control mice showed significant alterations in
receptor binding levels compared to vehicle control at subsequent
time points. Receptor binding levels in cortical homogenates of vehi
cle control animals on Day 11-53 were significantly depressed with the
exception of Day 47 compared to vehicle control animals on Day 1.
The next experiment was designed to: (a) determine if survival
times of mice exposed to hypoxic conditions could be altered by chronic
DFP administration and (b) determine if there is a correlation between
the number of central cholinergic receptors and survival times to hy
poxia.
Results from the [3H]QNB receptor binding assay are illustrated
in Table 7 and Figure 14 Panel A; the hypoxia survival time results
are shown in Table 8 and Figure 14 Panel B. On Day 5, after two doses
of DFP, QNB binding to central muscarinic receptor sites was not al
tered, but hypoxia survival times of DFP-treated mice (6.7 +0.5 min
utes) were significantly increased compared to vehicle control mice
(5.4 + 0.2 minutes). The 17th day of treatment (dose 6) was the first
time point at which there was a significant difference between the
level of central cholinergic receptor binding in cortical homogenates
of DFP-treated mice as compared to vehicle control animals. Receptor
numbers in the DFP treated mice were 86% of vehicle control levels on
Day 17 (significant Student t p<.05). Survival time of DFP-treated
mice in the hypoxia test (7.1 +0.3 minutes) was significantly in
creased compared to vehicle control mice (5.5 + 0.2 minutes) at this
same time point. Maximal DFP-induced subsensitivity of muscarinic
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TABLE 7: CORRELATION STUDY: TIME COURSE OF DEVELOPMENT AND RECOVERY OF DFP-INDUCED
CHOLINERGIC SUBSENSITIVITY IN C57BL/6J MICE
DAY POSE # OF DFP
SPECIFIC f3H JQNB BINDING
CONTROL (PMOLE/MG) DFP (PMOLE/MG) % CONTROL
17
35
41
60
12
14
20 DAYS POST
FINAL DFP DOSE
0.806 0.011
0.824 0.028
0.854 0.042
0.767 0.020
0.748 0.014
0.794 0.034
0.713 0.018
0.600 0.027
0.541 0.065
0.665 0.023
98.5 4.2
86.6 2.2 #
71.3 3.1
68.7 1.4 *
88.2 3.0
SIGNIFICANT STUDENT T TEST P-C05
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TABLE 8 : CORRELATION STUDY: HYPOXIA SURVIVAL TIMES DURING THE TIME COURSE OF
DEVELOPMENT AND RECOVERY OF DFP-INDUCED CENTRAL CHOLINERGIC
SUBSENSITIVITY OF C57BL/6J
DAY DOSE # OF DFP N MEAN SURVIVAL TIME * S.E.
MINUTES
17
35
41
60
12
14
15
20 DAYS POST FINAL
DOSE (#14) OF DFP
15
15
15
15
CONTROL
5.4 + 0.2
5.5 + 0.2
5.3 + 0.2
5.0 + 0.4
5.1 + 0.2
DFP
6.7 + 0.5 *
7.1 + 0.3 *
10.3 + 0.7 *
8.5 + 0.8 *
6.1 + 0.5
SIGNIFICANT STUDENT T TEST P<.05
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FIGURE 14
Correlation Study: Time course of development and recovery of DFP-
induced central cholinergic subsensitivity in C57BL/6J mice and
hypoxia survival times.
PANEL A
Results of time course of development and recovery of DFP-induced
central cholinergic subsensitivity in C57BL/6J mice (n=5).
PANEL B
Results of hypoxia survival times of C57BL/6J mice (n=5) during
time course of development and recovery of DFP-induced central
cholinergic subsensitivity.
* Significant p<.05 Student t test.
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receptors was measured after the 12th dose (Day 35) and the 14th dose
of DFP (Day 41). A comparison of the number of receptors in cortical
homogenates of DFP-treated mice on these days showed no statistical
difference between receptor levels in drug treated mice. At these
time points QNB binding to central muscarinic receptors was decreased
by 25-30% in DFP-treated mice when compared to QNB binding levels in
cortical homogenates of vehicle control mice. Hypoxia survival times
in DFP treated mice were significantly increased as compared to con
trol vehicle mice after the 12th (Day 35) and 14th doses (Day 41) of
DFP. By the 20th day after DFP withdrawal (Day 60) the number of
central cholinergic receptors in the cortical homogenates of DFP-treat
ed mice rose to 86% of the number of these receptors in vehicle con
trol mice (significant Student t p<.05). At this same time point,
20 days (Day 60) after drug withdrawal, there was no statistically
significant alteration in the hypoxia survival times of DFP-treated
mice compared to vehicle control survival times. Mean survival of
DFP-treated mice was 6.1 +0.5 minutes and vehicle control mice sur
vived an average of 5.1 + 0.2 minutes in the hypoxia test on Day 60.
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DISCUSSION
Numerous studies have demonstrated that survival time of experi
mental animals to hypoxic conditions can be altered by manipulation of
the central cholinergic nervous system (21-23). This type of screen
has been utilized to assess the effect of drugs on cholinergic neurons.
Scremin (21-22) has shown that drugs which enhance central cholinergic
activity increase hypoxia survival time, whereas drugs that reduce cen
tral cholinergic activity reduce survival time. These studies also
demonstrate that this effect is not mediated by peripheral cholinergic
receptors (22).
Our initial study was designed to determine if C57BL/6J mice were
an appropriate animal model to study the effects of centrally acting
cholinergic drugs on hypoxia survival times. A single intraperitoneal
injection of atropine sulfate in C57BL/6J mice was shown to decrease
hypoxia survival time by 39% when compared to the appropriate control
group. These results are similar to
Scremin'
s (21) who demonstrated
that atropine sulfate decreased survival time by 33% in mice. In con
trast to the effect of atropine sulfate on hypoxia survival times, a
single intraperitoneal dose of DFP increased the survival time of
C57BL/6J mice to hypoxic conditions by 30%. Scremin and Atru (21-23)
reported similar results for another acetylcholinesterase inhibitor,
physostigmine, in mice. Our results demonstrated that hypoxia survival
times of C57BL/6J were sensitive to acute alterations in central cho
linergic activity.
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Hypoxia survival times were obtained during a two hour period in
the morning during which all subsequent experiments were performed.
Reports have suggested that hypoxia survival times and cholinergic ac
tivity vary with time of day (28). Perry also reported thafcircadian
rhythms alter central cholinergic activity in man (29). Survival times
of C57BL/6J mice were assessed from 7:45 to 10:00 a.m. During this two
hour period, survival times of untreated C57BL/6J mice remained stable.
It has been well established that chronic treatment of experiment
al animals with DFP creates a cholinergic subsensitivity i.e. reduced
number of muscarinic receptors in the central nervous system (17-20).
Chronic administration of DFP has been shown to reduce the number but
not the affinity of the postsynaptic muscarinic receptor to cholinergic
antagonists (18). A QNB binding assay (16) was used to measure the
number and affinity of central cholinergic receptors. The mechanism
by which chronic DFP administration induces a reduction in the number
of central cholinergic receptors is thought to be due to acetylcholin
esterase inhibition and the accumulation of acetylcholine at cholin
ergic receptors (18,20).
Cholinergic subsensitivity has been reported to be evident to the
cerebral cortex of Alzheimer or senile dementia patients (7-9). If
artificially induced cholinergic subsensitivity could be created by
chronic DFP treatment, a suitable animal model may be developed which
can be utilized to screen drugs for potential pharmacological activity
in the treatment of certain aspects of senile dementia.
The [3H]QNB binding procedure was modified to measure the num
ber and affinity of central cholinergic receptors in C57BL/6J mice.
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[3H]QNB binding to the muscarinic receptor in mouse cerebral cortex
was linear in the range of tissue protein from 0.1 to 0.5 mg, which
agree well with previously published rodent data (16). The affinity
of the receptor, Kd, is 0.27 nM and the number of muscarinic binding
sites Bmax is 1.26 pmoles/mg, which are comparable to published values
for [3H]QNB binding in rodent cerebral cortex (16,18). The number of
muscarinic receptors in mouse cortical homogenates was determined with
a concentration of 0.7 nM [3H]QNB and was expressed as specific bind
ing (pmole/mg). At this concentration, maximal binding and a high
ratio of specific to nonspecific binding was obtained.
The onset and recovery of alterations in the number of central
muscarinic receptors were characterized in C57BL/6J mice chronically
treated with DFP. The maximal reduction in muscarinic receptor bind
ing to QNB in cerebral cortex of DFP-treated mice was 70-75% of con
trol animals, comparable to results previously reported (19). Cortical
muscarinic receptor binding to QNB gradually decreased with time under
a dose regimen of 1 mg/kg DFP administered every 72 hours for a total
of 14 doses (40 days). The first significant difference in the number
of central cholinergic receptors in DFP and vehicle control mice occur
red after the 6th dose of DFP (Day 17) with maximal reduction evident
after the 8th dose of DFP (Day 23). Receptor binding levels gradually
returned to control levels 13 days (Day 53) after the final dose of DFP.
Upon termination of DFP administration, acetylcholinesterase inactivated
by DFP was replaced by newly synthesized acetylcholinesterase which was
able to hydrolyze acetylcholine and reduced
its'
accumulation in the
central synapse. The formation of new acetylcholinesterase reduced
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hyperstimulation of central cholinergic neurons and this was thought
to stimulate the synthesis of new receptors, which was reflected in
increased [3H]QNB binding. Our data provides the first information
on the time course of replacement of central cholinergic receptors
following withdrawal of chronic DFP administration. The results of
this study indicated that at least 13 days are required for the number
of central muscarinic receptors to return to control levels following
chronic DFP administration. This study also showed that chronic ad
ministration of DFP may produce an "artificial
form"
of senility that
is reflected in a cholinergic subsensitivity similar to that seen in
Alzheimer's disease.
Next, we wanted to determine if these changes in cortical receptor
binding levels could be detected by utilizing the hypoxia screen. If
DFP-induced subsensitivity is to be utilized as a screening model, de
tection of small changes in central cholinergic activity could be sim
plified by monitoring these changes through the hypoxia screen.
Because our studies demonstrated that chronic administration of
DFP could reversibly alter the number of central cholinergic receptors,
we then examined the relationship between hypoxia survival times and
[3H]QNB binding to central cholinergic receptors. Presently, there
are no studies which report any relationship between DFP-induced changes
in receptor numbers and hypoxia survival times. Our results show that
after the 6th (Day 17), 12th (Day 35), and 14th (Day 41) dose of DFP
the survival times of C57BL/6J mice to hypoxia were significantly in
creased, while muscarinic receptor binding levels were significantly
reduced when compared to vehicle control mice. The increase in
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survival times on Days 5-41 (Dose 2-14) can possible be attributed to
acetylcholine which accumulated in the synapse and a concomitant hyper-
stimulation of available acetylcholine receptor sites.
In contrast to this inverse relationship between hypoxia surviv
al times and cholinergic receptor number, hypoxia survival times were
significantly increased after the second dose of DFP (Day 5), but re
ceptor number remained unaltered. In addition, hypoxia survival times
in mice in which DFP administration had been terminated 20 days prior
to testing on Day 60, were not significantly altered although there was
a significant decrease in the number of central cholinergic receptors.
The lack of correlation between receptor number and hypoxia survival
times on Day 60 may be explained by the fact that following DFP treat
ment, the amount of acetylcholine in the CNS (which contributed to pro
longed hypoxia survival times at the other time points) was gradually
reduced as new molecules of acetylcholinesterase were synthesized.
This study has characterized the time course of development and
recovery of central cholinergic subsensitivity to chronic DFP admin
istration in mice. This cholinergic subsensitivity (reduction in the
number of central muscarinic receptors) may be similar to that seen in
Alzheimer or senile dementia patients (7-9) and thus this model may
serve as a screen for pharmaceutical agents that could be developed to
treat or prevent Alzheimer's disease. The DFP-induced cholinergic sub
sensitivity model has the added advantage of circumventing the expense
of utilizing naturally aged animals for these studies.
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The hypoxia screen was evaluated for its ability to reflect small
changes in the number of muscarinic receptors in mouse cerebral cortex.
This study suggests that the hypoxia survival times may be sensitive
indicators of central cholinergic function, but are not a clear pre
dictor of the level of muscarinic receptor binding in cortical homog
enates. Further studies are needed to assess the utility of the hypox
ia screen as an indicator of the number of central cholinergic receptors.
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